Osivax secures strategic funding from Meiji Seika

French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, has announced the successful first close of its Series B financing, raising 10 million euros ($10.05 million) from new and existing investors.

Osivax said it is pleased to welcome Meiji Seika Pharma, a Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy spanning over 75 years, Meiji Seika Pharma is a subsidiary of the Meiji Group and brings extensive expertise in vaccine development and commercialization, the French firm noted.

The funds secured from Meiji Seika Pharma, new and existing investors, combined with non-diluted funding, will support the continued pre-clinical and clinical development of OVX836, Osivax’s broad-spectrum influenza vaccine candidate. This includes a Phase IIb field efficacy study, designed to evaluate OVX836 against placebo in a large cohort of 2,850 participants across multiple international sites. The study represents a significant step in advancing the science of influenza prevention beyond conventional approaches.